Tesaro Inc. (NASDAQ:TSRO) was up 3.3% during trading on Wednesday . The company traded as high as $92.47 and last traded at $92.27, with a volume of 369,752 shares traded. The stock had previously closed at $89.29.

A number of equities research analysts have recently commented on TSRO shares. FBR & Co raised their price objective on shares of Tesaro from $65.00 to $93.00 and gave the stock an “outperform” rating in a research note on Wednesday, June 29th. Mizuho raised their price objective on shares of Tesaro from $67.00 to $94.00 and gave the stock a “buy” rating in a research note on Tuesday, July 5th. Robert W. Baird started coverage on shares of Tesaro in a research note on Monday. They set an “outperform” rating and a $105.00 price objective on the stock. Jefferies Group cut shares of Tesaro from a “buy” rating to a “hold” rating and raised their price objective for the stock from $53.00 to $75.00 in a research note on Thursday, June 30th. They noted that the move was a valuation call. Finally, Leerink Swann raised their price objective on shares of Tesaro from $65.00 to $95.00 and gave the stock an “outperform” rating in a research note on Thursday, June 30th. Two research analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $76.50.

The firm’s 50-day moving average price is $60.39 and its 200 day moving average price is $46.35. The stock’s market cap is $4.23 billion.

Tesaro (NASDAQ:TSRO) last released its earnings results on Thursday, May 5th. The biopharmaceutical company reported ($2.22) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.69) by $0.53. The company earned $0.31 million during the quarter, compared to analysts’ expectations of $2.48 million. During the same quarter in the previous year, the business earned ($1.30) EPS. Equities research analysts forecast that Tesaro Inc. will post ($7.16) earnings per share for the current fiscal year.

In other news, VP Jeffrey H. Hanke sold 12,500 shares of the stock in a transaction dated Thursday, June 30th. The stock was sold at an average price of $74.35, for a total value of $929,375.00. Following the completion of the sale, the vice president now owns 12,500 shares in the company, valued at $929,375. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Edward C. English sold 7,000 shares of the stock in a transaction dated Friday, June 10th. The shares were sold at an average price of $40.75, for a total value of $285,250.00. Following the completion of the sale, the vice president now owns 3,500 shares of the company’s stock, valued at approximately $142,625. The disclosure for this sale can be found here.

Other large investors recently bought and sold shares of the company. Whittier Trust Co. raised its stake in Tesaro by 1.1% in the fourth quarter. Whittier Trust Co. now owns 20,945 shares of the biopharmaceutical company’s stock worth $1,096,000 after buying an additional 220 shares during the period. Rhumbline Advisers raised its stake in shares of Tesaro by 9.3% in the fourth quarter. Rhumbline Advisers now owns 22,403 shares of the biopharmaceutical company’s stock worth $1,172,000 after buying an additional 1,915 shares during the period. Bank of Montreal Can raised its stake in shares of Tesaro by 9,925.5% in the fourth quarter. Bank of Montreal Can now owns 24,362 shares of the biopharmaceutical company’s stock worth $1,275,000 after buying an additional 24,119 shares during the period. Nationwide Fund Advisors raised its stake in shares of Tesaro by 1.3% in the fourth quarter. Nationwide Fund Advisors now owns 26,647 shares of the biopharmaceutical company’s stock worth $1,394,000 after buying an additional 330 shares during the period. Finally, ProShare Advisors LLC acquired a new stake in shares of Tesaro during the fourth quarter worth $1,864,000.

TESARO, Inc (TESARO) is oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. The Company has in-licensed and are developing three clinical-stage product candidates, rolapitant, niraparib and TSR-011. Rolapitant is a potent and long-acting neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting (CINV); Niraparib, formerly known as MK-4827, is an orally active and potent poly (ADP-ribose) polymerase, and TSR-011 is an orally available targeted anti-cancer agent which is a potent inhibitor of both anaplastic lymphoma kinase (ALK) and tropomyosin-related kinase (TRK).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.